Chloroform fraction of *Scutellaria barbata* D. Don promotes apoptosis and suppresses proliferation in human colon cancer cells

LING ZHANG1,2, QIAOYAN CAI1,2, JIUMAO LIN1,2, YI FANG1,2, YOUZHI ZHAN1,2, ALING SHEN1,2, LIHUI WEI1,2, LILI WANG1,2 and JUN PENG1,2

1 Academy of Integrative Medicine and 2 Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China

Received June 3, 2013; Accepted December 2, 2013

DOI: 10.3892/mmr.2013.1864

**Abstract.** *Scutellaria barbata* D. Don (SB) has long been used as a major component in numerous Chinese medical formulas to clinically treat various types of cancer. Previously, we reported that the extracts of SB were able to suppress colon cancer growth *in vivo* and *in vitro*, possibly by inducing cancer cell apoptosis and inhibiting cell proliferation and tumor angiogenesis. However, the anticancer mechanisms of its bioactive ingredients remain largely unclear. In the present study, using three human colon cancer cell lines SW620, HT-29 and HCT-8, the antitumor effect of different solvent fractions of SB were evaluated and the potential underlying molecular mechanisms were investigated. Using an 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, it was revealed that the chloroform fraction of SB (ECSB) exhibited the most potent inhibitory effect on the growth of all three colon cancer cell lines and SW620 cells exhibited the most sensitive response to ECSB treatment (IC50=65 µg/ml). In addition, by performing fluorescence-activated cell sorting, transmission electron microscopy and colony formation assays, it was observed that ECSB significantly induced apoptosis and inhibited proliferation in SW620 cells in a dose-dependent manner. Furthermore, ECSB treatment resulted in the upregulation of the pro-apoptotic Bax/Bcl-2 ratio and a decrease in the expression of the pro-proliferative cyclin D1 and cyclin-dependent kinase 4. The results from the present study may provide a scientific foundation for the development of novel anticancer agents from the bioactive ingredients in the ECSB.

**Introduction**

Colorectal cancer (CRC) is one of the most serious malignancies with its incidence and mortality increasing annually (1). Although surgical resection offers the greatest prognosis, a substantial portion of CRC patients already present with metastatic disease at the time of diagnosis (2,3). Additionally, surgery is not always able to extirpate the recurrence of advanced CRC (4). Therefore, chemotherapy remains one of the major non-surgical therapeutic approaches for patients with advanced CRC. However, the efficacy and safety of the chemotherapies which are currently used remains a challenge due to severe toxicity, multidrug resistance and other side effects (5-7). Faced with these major problems, the development of novel anticancer agents is urgently required. Traditional Chinese medicine (TCM), dating back thousands of years, is important in the treatment of various diseases, including cancer (8-10). Clinical practice has also demonstrated that numerous TCMs are effective for the treatment of CRC (11).

*Scutellaria barbata* D. Don (SB) is a medicinal herb widely distributed in northeast Asia. As a well known traditional Chinese folk medicine, it has long been used to clinically treat various types of cancer (12-16). In particular, our previous studies demonstrated that the extracts of SB were able to suppress colon cancer growth *in vivo* and *in vitro*, possibly by inducing cancer cell apoptosis and inhibiting cell proliferation and tumor angiogenesis (16-18). However, the anticancer mechanisms of its bioactive ingredients are largely unclear. In the present study, using three human colon cancer cell lines SW620, HT-29 and HCT-8, the antitumor effect of different polar fractions of SB were evaluated and the potential underlying molecular mechanisms were investigated. It was revealed that the chloroform fraction of SB (ECSB) exhibited the most potent inhibitory effect on the growth of all three colon cancer cell lines and SW620 cells exhibited the most sensitive response to ECSB treatment. In addition, ECSB promoted apoptosis via the upregulation of the pro-apoptotic Bax/Bcl-2 ratio and inhibited proliferation by suppressing the expression of the pro-proliferative cyclin D1 and cyclin-dependent kinase 4 (CDK4) in SW620 cells.
Materials and methods

Materials and reagents. RPMI-1640 medium, KGML-15 SY medium, fetal bovine serum (FBS), penicillinstreptomycin and trypsin-EDTA were obtained from Hyclone (Carlsbad, CA, USA). TRIzol reagent and SuperScript II reverse transcriptase were purchased from Invitrogen Life Technologies (Grand Island, NY, USA). Anti-Bcl-2, Bax, Cyclin D1, CDK4 and β-actin antibodies, and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). A fluorescence-isothiocyanate (FITC)-conjugated Annexin V apoptosis detection kit was provided by Becton-Dickinson (San Jose, CA, USA). All the other chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Preparation of the SB extract. The herb was obtained from the Guo Yi Tang Chinese Herbal medicine store (FuJian, China). SB (500 g) was extracted three times with 5,000 ml of 85% ethanol using a refluxing method and filtered. The solvent was fractionated by a series of solvents, including petroleum ether, chloroform, ethyl acetate and N-butanol, to obtain the petroleum ether fraction of SB (EPESB), ECSB, ethyl acetate fraction of SB (EEASB) and the N-butanol fraction of SB (ENBSB). These fractions were then evaporated on a rotary evaporator. They were all dissolved in 100% dimethylsulfoxide (DMSO) to a stock concentration of 200 mg/ml and stored at -20°C. The final concentration of DMSO in the medium for all the experiments was ≤0.25%.

Cell culture. Human carcinoma SW620, HT-29 and HCT-8 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). SW620 cells were grown in L-15 medium and HT-29 and HCT-8 cells were cultured in RPMI-1640 medium, supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in 5% CO2 humidified air.

Cell viability using an 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell viability was assessed by an MTT colorimetric assay. SW620, HT-29 and HCT-8 cells were seeded into 96-well plates at a density of 5×103, 3×104 and 1×105 cells/ml in 2 ml medium. Following treatment with various concentrations of ECSB for 48 h, cells were harvested and rinsed three times with PBS buffer. The medium was replaced with fresh medium every three days. Following 14 days, cells were fixed with 10% formaldehyde, stained with 0.01% crystal violet and counted. The cell survival rate was calculated by normalizing the survival rate of the control cells to 100%.

Observation of ultrastructural characteristics by transmission electron microscopy (TEM). Cells were fixed with 1.5% paraformaldehyde and 3% glutaraldehyde in 0.1 mol/l sodium cacodylate buffer (pH 7.2-7.4) at 4°C for 24 h. The cell suspensions were then rinsed twice with phosphate-buffered saline (PBS) and post-fixed with 1% osmic acid in 0.1 mol/l sodium cacodylate buffer for 2 h. The cells were dehydrated in a graded series of alcohol and embedded with epoxy resin 618. Ultrathin sections (80 nm) were mounted on the copper wire mesh grids, air-dried, stained with 2.0% uranyl acetate for 1 min and counterstained with lead citrate for 15 min. The sections were examined and images were captured using a Hitachi 7650 electron microscope (Tokyo, Japan).

 Colony formation. SW620 cells were seeded into 6-well plates at a density of 5×103 cells/ml in 2 ml medium. Following treatment with various concentrations of ECSB for 48 h, cells were harvested and diluted in 2 ml fresh medium without ECSB, and then each well was reseeded at a density of 1,000 cells per well. The medium was replaced with fresh medium every three days. Following 14 days, cells were fixed with 10% formaldehyde, stained with 0.01% crystal violet and counted. The cell survival rate was calculated by normalizing the survival rate of the control cells to 100%.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis. SW620 cells were exposed to various concentrations of ECSB for 48 h and then total RNA was isolated with TRIzol reagent (Invitrogen Life Technologies). First-strand cDNA was generated via reverse transcription of 2 µg total RNA using Oligo(dT) primer and SuperScript II reverse transcriptase according to the manufacturer’s instructions. The obtained cDNA was used to determine the mRNA levels of Bax, Bcl-2, Cyclin D1 and CDK4 by PCR with TaqDNA polymerase (Fermentas, Vilnius, Lithuania). GAPDH was used as an internal control.

Western blot analysis. SW620 cells were treated with various concentrations of ECSB for 48 h. Adherent and floating cells were harvested and rinsed three times with PBS buffer. The cells were lysed with radioimmunoprecipitation assay lysis buffer (Pierce Chemical Co., Rockford, Illinois, USA) containing phenylmethylsulfonyl fluoride and extracts were quantified using the bicinchoninic acid protein assay (Pierce Chemical Co.) The proteins (30 µg) were separated by 12% SDS-PAGE gels and transferred onto polyvinylidene fluoride membranes (Millipore Corporation, Billerica, MA, USA). The membranes were incubated with 5% skimmed milk and probed with primary antibodies against Bax, Bcl-2, cyclin D1, CDK4 and β-actin (1:1,000) overnight at 4°C. The membranes were rinsed three times with Tris-buffered saline with Tween-20 (TBST) and then the appropriate HRP-conjugated secondary antibodies were diluted at 1:5,000 in blocking solutions for 1 h at room temperature. Following washing again in TBST, the
membranes were detected by enhanced chemiluminescence. β-actin was used as an internal control.

Statistical analysis. Data were analyzed using the SPSS package for Windows (version 13.0; SPSS Inc., Chicago, IL, USA). The quantitative data are expressed as the mean ± standard deviation. Statistical analysis of the data was performed using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results and Discussion

ECSB exhibits the most potent inhibitory effect on the growth of colon cancer cells. By performing an MTT assay in three human colon cancer cell lines, SW620, HT-29 and HCT-8, the in vitro anticancer effect of different fractions of SB, including EPESB, ECSB, EEASB and ENSB, was compared. As shown in Fig. 1, all the fractions inhibited the viability of three cancer cells in a dose-dependent manner. In particular, ECSB exhibited the most potent antitumor activity in SW620 cells, with an IC_{50} of 65 µg/ml. To further examine the mode of action of ECSB, SW620 cells were selected for the following study.

ECSB promotes apoptosis and inhibits the proliferation of SW620 cells. Apoptosis eliminates excess, redundant, abnormal cells in animals and thus is crucial for animal development and tissue homeostasis. Disturbed regulation of this vital process represents a major causative factor in tumorigenesis (19). Therefore, in order to determine the mechanism of the growth suppressive activity of ECSB, its effect on apoptosis in SW620 cells was examined. The in vitro cell apoptosis was assessed via Annexin V/PI staining followed by FACS analysis. As shown in Fig. 2, the percentage of cells undergoing either early apoptosis or late apoptosis following treatment with 0, 25, 50 and 75 µg/ml ECSB was 6.80, 11.54, 33.53 and 65.12%, respectively (P<0.05), suggesting that ECSB
treatment significantly induced apoptosis in SW620 cells in a dose-dependent manner.

In order to verify these results, TEM was used to observe ultrastructural changes in SW620 cells following ECSB treatment. As shown in Fig. 3, untreated cells exhibited a normal ultrastructure, including numerous microvilli on the cell surface, evenly distributed chromatin, a large nucleolus in the nucleus and numerous large mitochondria in the cytoplasm. By contrast, following treatment with ECSB, SW620 cells underwent significant ultrastructural changes that represented the typical morphological features of apoptosis, including a low nucleus/cytoplasm ratio, chromatin margination and condensation, formation of vacuoles in the mitochondria, formation of secondary lysosomes, loss of cellular microvilli and mitochondrial cristae. These data further demonstrated the pro-apoptotic activity of ECSB.

Cancer cells are also characterized by uncontrolled proliferation, therefore, inhibiting the excessive proliferation of tumor cells is one of the key approaches for the development of anticancer drugs. In order to determine the effect of ECSB on the proliferation of cancer cells, the survival rate in ECSB-treated SW620 cells was evaluated using a colony formation assay. As shown in Fig. 4, treatment with 25, 50 and 75 µg/ml ECSB for 48 h, respectively, reduced the survival rate of SW620 cells to 93.42, 54.82 and 5.85%, as compared with the untreated control cells (P<0.05), suggesting that ECSB suppressed the proliferation of colon cancer cells in a dose-dependent manner.

**ECSB regulated the expression of Bax, Bcl-2, cyclin D1 and CDK4.** Bcl-2 family proteins are key regulators of apoptosis, functioning as either suppressors, including Bcl-2, or promoters, including Bax (20). Tissue homeostasis is maintained by controlling the ratio of active anti- and pro-apoptotic Bcl-2 family proteins. A higher Bcl-2/Bax ratio caused by aberrant expression of the proteins is commonly found in various types of cancer, which not only confers a survival advantage to the cancer cells, but also results in drug resistance. Eukaryotic cell proliferation is primarily regulated by the cell cycle. G1/S transition is one of the main checkpoints of the cell cycle.

Figure 2. Effect of ECSB on the apoptosis of SW620 cells. (A) Following starvation for 12 h, SW620 cells were incubated for 24 h at various concentrations of ECSB and then cells were collected and stained with Annexin V/PI followed by FACS analysis. (B) Quantification of FACS analysis. The data are expressed as the mean ± standard deviation (error bars) from three independent experiments. *P<0.01, vs. the untreated control cells. ECSB, chloroform fraction of Scutellaria barbata D. Don; FACS, fluorescence-activated cell sorting; PI, propium iodide; FITC, fluorescein isothiocyanate.
Figure 3. Effect of ECSB on the ultrastructural changes of SW620 cells. Cells were treated with the indicated concentrations of ECSB for 48 h and ultrastructural changes were observed using transmission electron microscopy. Images were captured at a magnification of x15,000. Images are representative of three independent experiments. n, nucleus; m, mitochondria; mi, microvilli; cm, chromatin margination; cc, chromatin condensation; sl, secondary lysosome; ECSB, chloroform fraction of *Scutellaria barbata* D. Don.

Figure 4. Effect of ECSB on the proliferation of SW620 cells. Cells were treated with the indicated concentrations of ECSB for 48 h. (A) Cell survival rate was determined by a colony formation assay. (B) Quantification of colony formation. The data are expressed as the mean ± standard deviation (error bars) from three independent experiments. **P<0.01, vs. the untreated control cells. ECSB, chloroform fraction of *Scutellaria barbata* D. Don.

Figure 5. Effect of ECSB on the expression of Bcl-2, Bax, cyclin D1 and CDK4 in SW620 cells. Cells were treated with the indicated concentrations of ECSB for 48 h. (A) mRNA expression of Bcl-2, Bax, Cyclin D1 and CDK4 were evaluated by RT-PCR. (B) Protein expression levels of Bcl-2, Bax, cyclin D1 and CDK4 were determined by western blotting. GAPDH and β-actin were used as the internal controls for the RT-PCR or western blotting, respectively. Images are representative of three independent experiments. ECSB, chloroform fraction of *Scutellaria barbata* D. Don; CDK4, cyclin dependent kinase 4; RT-PCR, reverse transcription-polymerase chain reaction.
and is responsible for the initiation and completion of DNA replication. G1/S progression is regulated by cyclin D1, which exerts its function via forming an active complex with its CDK major catalytic partners (CDK4/6) (21,22). An unchecked or hyperactivated cyclin D1/CDK4 complex often leads to uncontrolled cell division and malignancy (23-25).

In order to further examine the mechanisms of the pro-apoptotic and antiproliferative activities of ECSB, RT-PCR and western blot analysis were performed to examine the expression of Bax, Bcl-2, cyclin D1 and CDK4. As shown in Fig. 5, ECSB significantly reduced the mRNA and protein expression of anti-apoptotic Bcl-2 as well as the pro-proliferative cyclin D1 and CDK4, whereas that of pro-apoptotic Bax was markedly increased following ECSB treatment.

In conclusion, the present study demonstrated that ECSB exhibited a potent inhibitory effect on colon cancer cell growth, which was mediated by its pro-apoptotic and antiproliferative activity. These results provide a strong scientific foundation for the development of novel anticancer agents from the bioactive ingredients in ECSB.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81073097).

References